Regulatory News: Aelis Farma (ISIN code: FR0014007ZB4 ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases (the Company »),
An exceptional fiscal year 2021, marked by positive phase 2a results for AEF0117, the recognition of the first sub-licensing revenues thanks to the signature of an industrial partnership with Indivior PLC, and securing major grants for AEF0217 (EU’s Horizon 2020 program) and AEF0117 (NIH-NIDA USA).A solid financial.
16.02.2022 - Regulatory News: Aelis Farma (Paris: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases (the Company ), announces today the successful completion of its initial public offering on .
Capital increase of approximately €25 million, i.e. 100% of the initial objective, despite high market volatility Size of the transaction which may be increased to approximately €25.55 million
02.02.2022 - Regulatory News: Not to be distributed, directly or indirectly, in the United States of America, Canada, Australia, Japan or South Africa. Aelis Farma, a clinical-stage biopharmaceutical company specializing in the development of treatments for .